Last reviewed · How we verify
variation of mannitol dose
variation of mannitol dose is a Osmotic diuretic Small molecule drug developed by University Hospital, Grenoble. It is currently FDA-approved for Reduction of intracranial pressure in head trauma and neurosurgery, Reduction of intraocular pressure in acute glaucoma, Promotion of diuresis in acute kidney injury and oliguria.
Mannitol is an osmotic diuretic that draws fluid into the renal tubules and bloodstream to reduce intracranial pressure and promote diuresis.
Mannitol is an osmotic diuretic that draws fluid into the renal tubules and bloodstream to reduce intracranial pressure and promote diuresis. Used for Reduction of intracranial pressure in head trauma and neurosurgery, Reduction of intraocular pressure in acute glaucoma, Promotion of diuresis in acute kidney injury and oliguria.
At a glance
| Generic name | variation of mannitol dose |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Drug class | Osmotic diuretic |
| Modality | Small molecule |
| Therapeutic area | Neurology, Ophthalmology, Critical Care |
| Phase | FDA-approved |
Mechanism of action
Mannitol works by creating an osmotic gradient in the kidney that prevents water reabsorption in the tubules, thereby increasing urine output and reducing total body fluid volume. This osmotic effect also reduces intracranial and intraocular pressure by drawing fluid from the brain and eye tissues into the intravascular space. Dose variations allow titration of the diuretic and pressure-reducing effects based on clinical need.
Approved indications
- Reduction of intracranial pressure in head trauma and neurosurgery
- Reduction of intraocular pressure in acute glaucoma
- Promotion of diuresis in acute kidney injury and oliguria
Common side effects
- Dehydration
- Electrolyte imbalance (hypernatremia, hypokalemia)
- Rebound intracranial pressure elevation
- Headache
- Nausea and vomiting
- Thrombophlebitis at injection site
Key clinical trials
- Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol (PHASE4)
- Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests (NA)
- Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes (NA)
- Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring (PHASE4)
- Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- variation of mannitol dose CI brief — competitive landscape report
- variation of mannitol dose updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI
Frequently asked questions about variation of mannitol dose
What is variation of mannitol dose?
How does variation of mannitol dose work?
What is variation of mannitol dose used for?
Who makes variation of mannitol dose?
What drug class is variation of mannitol dose in?
What development phase is variation of mannitol dose in?
What are the side effects of variation of mannitol dose?
Related
- Drug class: All Osmotic diuretic drugs
- Manufacturer: University Hospital, Grenoble — full pipeline
- Therapeutic area: All drugs in Neurology, Ophthalmology, Critical Care
- Indication: Drugs for Reduction of intracranial pressure in head trauma and neurosurgery
- Indication: Drugs for Reduction of intraocular pressure in acute glaucoma
- Indication: Drugs for Promotion of diuresis in acute kidney injury and oliguria
- Compare: variation of mannitol dose vs similar drugs
- Pricing: variation of mannitol dose cost, discount & access